Systemic Lupus Erythematosus Clinical Trial
— ADDRESSOfficial title:
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Dose-Response Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosis (SLE) is an autoimmune disease, meaning that the body's immune
system attacks its own organs and tissues. Within the immune system, B-cells and plasma
cells make proteins called antibodies, which in autoimmune disease can bind to one's own
tissues and are thus referred to as autoantibodies. Atacicept blocks 2 factors in the body,
called BLyS and APRIL, which are important for the maintenance of B-cells and plasma cells,
and thus the production of antibodies. This study will assess whether treatment with
atacicept can reduce SLE disease activity. Atacicept is still an experimental drug, meaning
that it is not available outside of a clinical trial, and that its potential benefits and
risks have not been fully determined.
A total of 175 subjects are planned to be randomized (35 subjects per treatment arm) in a
1:1:1:1:1 ratio to receive either atacicept 5 mg, atacicept 25 mg, atacicept 75 mg,
atacicept 115 mg or matching placebo, given subcutaneously once weekly for 24 weeks.
The primary objective of the trial is to evaluate the efficacy of atacicept compared to
placebo in reducing SLE disease activity in subjects treated with standard of care (SoC)
therapy and to investigate the dose-response relationship.
The secondary objectives of the trial are:
- To evaluate the effect of atacicept in reducing corticosteroid usage
- To evaluate the safety and tolerability profile of atacicept in subjects with SLE
- To confirm the PK and PD profiles of atacicept in SLE subjects
- To evaluate the changes in the Medical Outcomes Study Short Form General Health Survey
[SF-36].
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 2014 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female of =18 years of age - Written informed consent - Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of their illness - Disease duration of at least 6 months - SLEDAI-2K score = 6 at screening - Positive test results for antinuclear antibody (ANA) (HEp-2 ANA =1:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (=30 IU/mL) at screening - Negative serum pregnancy test and highly effective method of contraception for woman of childbearing potential. Exclusion Criteria: - Increase in dosing of corticosteroids within 2 weeks prior to screening - Introduction of MMF within 3 months prior to TD1 or increase in dosing within 1 month before screening - Change in dosing of immunosuppressants or corticosteroids during the screening period - Serum IgG < 6g/L - Estimated Glomerular Filtration Rate (GFR) <50 mL/min/1.73m² - Urinary protein:creatinine ratio >2 mg/mg - History of demyelinating disease - Breastfeeding or pregnancy - Legal or limited legal capacity Additional exclusion criteria also apply |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
EMD Serono |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline (trial day 1) in SLEDAI-2K Responder Index-50 (SRI-50) at week 24 of therapy | The SRI-50 is a modification of the SLEDAI-2K, and allows detection of partial improvements (at least 50%) in SLE signs and symptoms assessed by SLEDAI-2K (Systemic Lupus Erythamtosus Disease Activity Index- 2000). | 24 weeks | No |
Secondary | Change from baseline to Week 24 in corticosteroid dose | 24 weeks | No | |
Secondary | Change from baseline in serum Complement C3 levels at week 24 in subjects with low C3 at baseline | 24 weeks | No | |
Secondary | Change from baseline in serum Complement C4 levels at week 24 in subjects with low C4 at baseline | 24 weeks | No | |
Secondary | Change from baseline in anti-dsDNA antibodies (in subjects with anti dsDNA =30 IU/mL at baseline) and in ANA levels (in subjects with HEp-2 ANA =1:80 at baseline) at week 24 | 24 weeks | No | |
Secondary | Change from baseline in levels of total Ig and Ig classes (IgG, IgA, and IgM) at week 24 | 24 weekls | No | |
Secondary | The nature (preferred terms) and incidence of AEs | Frequency tables summarizing the observed number of AEs by System Organ Class (SOC) and preferred term will be presented per regimen | 24 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |